Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.22M | 8.33M | 9.92M | 12.87M | 14.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.22M | 8.33M | 9.92M | 12.87M | 14.16M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.22M | 8.33M | 9.92M | 12.87M | 14.16M |
| SG&A Expenses | 29.18M | 28.11M | 27.98M | 28.73M | 27.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.94M | 94.95M | 92.40M | 89.93M | 93.30M |
| Operating Income | -83.71M | -86.62M | -82.49M | -77.06M | -79.15M |
| Income Before Tax | -86.77M | -89.30M | -22.77M | -114.34M | -118.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.77 | -89.30 | -22.77 | -114.34 | -118.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.77M | -89.30M | -22.77M | -114.34M | -118.01M |
| EBIT | -83.71M | -86.62M | -82.49M | -77.06M | -79.15M |
| EBITDA | -82.51M | -85.38M | -81.18M | -75.72M | -77.78M |
| EPS Basic | -0.34 | -0.36 | -0.06 | -0.90 | -1.19 |
| Normalized Basic EPS | -0.18 | -0.20 | -0.01 | -0.54 | -0.73 |
| EPS Diluted | -0.34 | -0.36 | -0.06 | -0.90 | -1.19 |
| Normalized Diluted EPS | -0.18 | -0.20 | -0.01 | -0.54 | -0.73 |
| Average Basic Shares Outstanding | 1.04B | 1.00B | 942.49M | 800.37M | 631.79M |
| Average Diluted Shares Outstanding | 1.04B | 1.00B | 942.49M | 800.37M | 631.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |